La complejidad de la angioplastia puede definir el tiempo de doble antiagregación

Angioplasty Complexity May Define the Duration of Dual Antiplatelet Therapy

The DAPT study concluded that continued thienopyridine plus aspirin beyond a year after coronary angioplasty is associated with a decrease in the rate of stent thrombosis and major cardiovascular events. In contrast, there is a significant increase in moderate to severe bleeding when compared with continued aspirin alone. Based on the outcomes of this and<a href="https://solaci.org/en/2017/11/21/angioplasty-complexity-may-define-the-duration-of-dual-antiplatelet-therapy/" title="Read more" >...</a>

drug elutin baloon_reestenosis_instrastent

Efficacy of Micromesh-Covered Stents in Carotid Artery Stenting

Most literature, old and recent, associates carotid artery stenting with a higher rate of stroke (although minor) when compared with carotid endarterectomy during the acute period. However, 30-day outcomes of angioplasty and surgery are comparable. Many technical advancements, including new stent designs and different cerebral protection mechanisms, have improved the outcomes of angioplasty in clinical<a href="https://solaci.org/en/2017/11/10/efficacy-of-micromesh-covered-stents-in-carotid-artery-stenting/" title="Read more" >...</a>

TCT 2017 | SENIOR: DES con polímero reabsorbible y tiempo de doble antiagregación corto en pacientes añosos

TCT 2017 | SENIOR: DES with a Bioresorbable Polymer and Short Dual Antiplatelet Therapy in Elderly Patients

 Courtesy of the SBHCI. This study sought to assess the safety and efficacy of an everolimus-eluting stent with a biodegradable polymer (SYNERGY II) vs. a conventional stent (REBEL) in patients >75 years old with short duration of dual antiplatelet therapy. Before randomization, investigators recorded the planned duration of dual antiplatelet therapy (1 month for stable patients and 6 months<a href="https://solaci.org/en/2017/11/03/tct-2017-senior-des-with-a-bioresorbable-polymer-and-short-dual-antiplatelet-therapy-in-elderly-patients/" title="Read more" >...</a>

TCT 2017 | REDUCE: 3 vs 12 meses de doble antiagregación con el nuevo DES Combo

TCT 2017 | REDUCE: 3 vs 12 Months of Dual Antiplatelet Therapy with the New Combo DES

Courtesy of SBHCI. This new device has, on one hand, an abluminal sirolimus coating, and on the other hand, a luminal CD34 antibody coating for EPC capturing, to potentially accelerate post-PCI reendothelization. Between 2014 and 2016, the study included 1496 patients undergoing acute coronary syndrome (ACS), receiving the new COMBO stent. These patients were randomized<a href="https://solaci.org/en/2017/11/03/tct-2017-reduce-3-vs-12-months-of-dual-antiplatelet-therapy-with-the-new-combo-des/" title="Read more" >...</a>

TCT 2017 | INTREPID: reemplazo mitral con prótesis autoexpandible

TCT 2017 | INTREPID: Mitral Replacement with a Self-Expanding Device

Courtesy of the SBHCI. Intrepid is a 43-, 46-, and 50-mm nitinol self-expanding valve with bovine pericardial leaflets that is placed using a transapical delivery system with a 35-Fr access. This pilot study enrolled 50 patients with severe mitral regurgitation who were symptomatic and at a high surgical risk, or in whom surgery was contraindicated. Read<a href="https://solaci.org/en/2017/11/03/tct-2017-intrepid-mitral-replacement-with-a-self-expanding-device/" title="Read more" >...</a>

ABSORB III: a 3 años continua la desilusión de la plataforma bioabsorbible

ABSORB III: after 3 Years, the Bioresorbable Scaffold is Still a Disappointment

Courtesy of the SBHCI. The 3-year outcomes of the ABSORB III trial, which randomized 2008 patients 2:1 to an everolimus eluting bioresorbable scaffold (1322 patients) vs. a metallic stent with permanent everolimus eluting polymer (686 patients), was published with low profile and great disappointment. Primary end-point, a composite of target vessel failure, occurred in 13.4% of patients receiving<a href="https://solaci.org/en/2017/11/02/absorb-iii-after-3-years-the-bioresorbable-scaffold-is-still-a-disappointment/" title="Read more" >...</a>

Absorb IV: la plataforma bioabsorbible con una técnica de implante perfeccionada

Absorb IV: Bioresorbable Scaffolds with an Optimized Implantation Technique

 Courtesy of the SBHCI. The Absorb IV trial randomized 2604 patients in a 1:1 ratio to receive an Absorb everolimus-eluting bioresorbable scaffold or a Xience stent. With the aim of minimizing the problems observed in previous studies, the Absorb IV protocol excluded small caliber (<2.5 mm) vessels and included mandatory aggressive pre-dilation followed by non-complacent balloon post-dilation. Patients could<a href="https://solaci.org/en/2017/11/02/absorb-iv-bioresorbable-scaffolds-with-an-optimized-implantation-technique/" title="Read more" >...</a>

DKCRUSH-V: lo más simple no siempre es lo mejor en el tronco de la coronaria izquierda

DKCRUSH-V: What Is Simple Is Not Always Best for the Left Main Coronary Artery

Courtesy of the SBHCI. Angioplasty of true distal left main bifurcation lesions with a double-kissing (DK) crush two-stent strategy, compared with provisional stenting, results in lower rates of target lesion failure at 1 year. These findings were largely driven by lower rates of target vessel infarction and definite/probable stent thrombosis. Read also: “EXCEL-QOL Substudy: Similar Quality<a href="https://solaci.org/en/2017/11/01/dkcrush-v-what-is-simple-is-not-always-best-for-the-left-main-coronary-artery/" title="Read more" >...</a>

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

Fentanyl in Angioplasty: What Is the Price of More Comfort During the Procedure?

Fentanyl is a potent opiate commonly administered in the cath lab. Recently, questions on its safety have been raised by research demonstrating that intravenous morphine significantly delays the absorption of oral P2Y12 platelet inhibitors. The mechanism might be slowed gastric emptying. The Platelet Aggregation with tiCagrelor Inhibition and FentanYl (PACIFY) trial enrolled 212 patients undergoing indicated<a href="https://solaci.org/en/2017/10/31/fentanyl-in-angioplasty-what-is-the-price-of-more-comfort-during-the-procedure/" title="Read more" >...</a>

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?

2.0-mm DES for Very Small Vessels: Are They Viable?

The reference vessel diameter is a fundamental factor for restenosis after coronary angioplasty even with drug-eluting stents. The smallest sized stents available are 2.25 mm in diameter, but even smaller vessels can be symptomatic. This was a prospective multicenter trial of the Resolute Onyx 2.0-mm zotarolimus-eluting stent. The primary endpoint was target lesion failure. Read also: “Effects<a href="https://solaci.org/en/2017/10/25/2-0-mm-des-for-very-small-vessels-are-they-viable/" title="Read more" >...</a>